| Date | Title | Description |
| 01.09.2026 | AstraZeneca completes agreement for Zegfrovy | AstraZeneca completes agreement for Zegfrovy
Tue, Sep 01, 2026 08:05 CET Report this content
01 September 2026
AstraZeneca completes global license agreement
for oral EGFR inhibitor Zegfrovy for lung cancer
AstraZeneca today announced the s... |
| 21.08.2026 | Dizal to Present Emerging Data on ZEGFROVY® in Non-Small Cell Lung Cancer at WCLC 2026 | SHANGHAI, Aug. 21, 2026 /PRNewswire/ -- Dizal (SSE: 688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that the latest clinical data on its no... |
| 15.07.2026 | AstraZeneca Licenses Zegfrovy From Dizal In Deal Worth Up To $1.5 Billion | AstraZeneca has entered into an exclusive global licensing agreement with Dizal Pharmaceutical for Zegfrovy, an oral targeted therapy approved in the U.S. and China for certain patients with non-small cell lung cancer.
Under the agreement, ... |
| 14.07.2026 | AstraZeneca licenses novel EGFR inhibitor | AstraZeneca licenses novel EGFR inhibitor
Tue, Jul 14, 2026 08:00 CET Report this content
14 July 2026
AstraZeneca enters exclusive global license agreement for novel oral
EGFR inhibitor Zegfrovy for lung cancer with Dizal Pharmaceutical
Co... |
| 31.05.2026 | Dizal Presents Positive NSCLC Data for Fourth-Generation EGFR TKI DZD6008 and Golidocitinib in Combination with Anti-PD-1 at ASCO 2026 | Oral presentation of DZD6008 demonstrated strong and durable anti-tumor activity, excellent BBB-penetrant properties, and a favorable safety profile in patients relapsed from third-generation EGFR TKI
In treatment-naïve patients with advanc... |
| 29.05.2026 | Dizal Announces Phase 3 WU-KONG28 Results: ZEGFROVY® (Sunvozertinib) Outperforms Platinum-Doublet Chemotherapy in First-Line EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer | ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20ins
WU-KONG28 is the first global randomized phase 3 study with positive results for ... |
| 27.05.2026 | Dizal's ZEGFROVY® (Sunvozertinib) New Drug Application Accepted and Granted Priority Review by China National Medical Products Administration for First-Line Treatment of EGFR Exon 20 Insertion-Mutated... | SHANGHAI, May 27, 2026 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of oncology and hematological diseases, announced that the Center for Drug Evaluation (CDE) of ... |
| 21.03.2026 | Dizal Announces Positive Topline Phase 3 Results from WU-KONG28 Study: Evaluating Oral, Once-Daily ZEGFROVY® (Sunvozertinib) vs. Platinum-Containing Chemo Doublet in First-Line Non-Small Cell Lung Can... | Treatment with ZEGFROVY® resulted in statistically significant and clinically meaningful improvement in progression free survival (PFS) over platinum-containing chemo doublet
WU-KONG 28 is the first and only phase 3 study to demonstrate mea... |
| 09.12.2025 | Dizal Showcases its Strong Hematology Pipeline with New Data from Golidocitinib and Birelentinib at ASH 2025 | SHANGHAI, Dec. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for cancer and immunological diseases, announced new data from its hematology portfolio at the 67th American Soci... |
| 09.09.2025 | Dizal Showcases Robust Portfolio of Lung Cancer Studies at 2025 WCLC | SHANGHAI, Sept. 9, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced the presentation of new findings on its leadin... |
| 06.08.2025 | The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma | Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL
Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pret... |
| 16.07.2025 | China's domestic biotech industry is becoming a global force | China's domestic biotech industry is entering a new phase of international influence, as homegrown innovative drugs increasingly meet global clinical demand. One recent example is Dizal Pharma, a Wuxi-based biotech firm that has emerged as ... |
| 03.07.2025 | Dizal's ZEGFROVY® (sunvozertinib) Receives FDA Accelerated Approval as the Only Targeted Oral Treatment for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | ZEGFROVY is the only approved targeted oral treatment for NSCLC with EGFR exon20ins
Approval follows the U.S. FDA's Priority Review and is supported by the pivotal WU-KONG1 Part B study, in which ZEGFROVY demonstrated statistically signific... |
| 19.06.2025 | Dizal Completes Enrollment for its Phase III Pivotal Study of Sunvozertinib vs. Platinum Doublet in Treatment Naïve NSCLC Patients with EGFR Exon20 Insertional Mutations | SHANGHAI, June 19, 2025 /PRNewswire/ -- Dizal announced the completion of patient enrollment for its WU-KONG28 clinical trial: a multinational, randomized phase III study evaluating the efficacy and safety of sunvozertinib versus platinum-b... |
| 12.06.2025 | Dizal Showcases Two First-in-Class Therapies in Hematologic Malignancies at EHA and ICML 2025 | Golidocitinib demonstrated promising efficacy in maintaining and enhancing tumor response in peripheral T-cell lymphoma (PTCL) post first-line therapy with a 24-month disease-free survival (DFS) rate of 74.2%
DZD8586 exhibited significant a... |
| 26.05.2025 | Dizal to Highlight its Portfolio Advances in Hematologic Malignancies and Lung Cancer at ASCO 2025 | DZD8586 demonstrated significant anti-tumor efficacy in heavily pretreated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) patients with ORR of 84.2%
DZD6008, a BBB-penetrant 4th generation EGFR TKI, showed encouraging and... |
| 15.05.2025 | Dizal to Present Promising Clinical Data on Golidocitinib and DZD8586 for the Treatment of Lymphoma at the Coming International Hematology Conferences | The latest 2-year follow-up data on golidocitinib as a maintenance therapy for peripheral T-cell lymphoma (PTCL) patients who achieved tumor response after first-line systemic therapy will be presented orally at the 2025 ICML
A pooled safet... |
| 24.04.2025 | Dizal to Showcase Data in Hematologic Malignancies and Lung Cancer at ASCO 2025 | DZD8586 study results in B-cell non-Hodgkin lymphomas (B-NHLs) were selected for oral and poster presentations. The analysis in chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) after covalent or non-covalent BTK inhibitors ... |
| 01.04.2025 | Dizal Announces DZD8586 and DZD6008 Presentations at 2025 ASCO Annual Meeting | SHANGHAI, April 1, 2025 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced today that results of its investigational drug... |
| 20.03.2025 | Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer | Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL
The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC
SHANGHAI, March 20, 2025 ... |
| 07.01.2025 | U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application | If approved, Sunvozertinib as a single oral drug would offer a convenient and safe treatment option with superior efficacy for NSCLC patients with EGFR exon20ins
Sunvozertinib's NDA was submitted based on the multinational pivotal WU-KONG1 ... |
| 12.12.2024 | Dizal's Innovative Advances in Cancer Treatment: A New Dawn for Patients | In the realm of cancer treatment, innovation is the lifeblood that fuels hope. Dizal, a biopharmaceutical company based in Shanghai, is at the forefront of this revolution. With two promising drugs, sunvozertinib and DZD8586, Dizal is tackl... |
| 11.12.2024 | Dizal Announces Positive Pooled Data of Sunvozertinib in EGFR Tyrosine Kinase Inhibitor-Resistant Non-Small Cell Lung Cancer Published in Lung Cancer | Sunvozertinib, as a single agent, demonstrated promising antitumor activity and favorable safety profile in heavily pretreated patients with EGFR-mutated NSCLC who had developed resistance to EGFR TKI treatment
SHANGHAI, Dec. 11, 2024 /PRNe... |
| 09.12.2024 | Dizal Presents Latest Data of DZD8586, a LYN/BTK Dual Inhibitor, in B-cell Non-Hodgkin Lymphoma at the 2024 ASH Annual Meeting | DZD8586 demonstrated encouraging anti-tumor activity with manageable safety and favorable pharmacokinetic (PK) characteristics in patients with B-NHL
SHANGHAI, Dec. 9, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company com... |
| 08.11.2024 | Dizal Submits New Drug Application to the U.S. FDA for Sunvozertinib in Treating Relapsed or Refractory Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | The submission is supported by data from the pivotal WU-KONG1 Part B study, which featured in an oral session at the 2024 ASCO Annual Meeting
Sunvozertinib is the world's first and only oral drug approved for NSCLC patients with EGFR exon20... |
| 29.10.2024 | China’s Medical Insurance Talks Feature Record Number of Orphan Drugs | (Yicai) Oct. 29 -- This year's negotiations to include drugs in China's national medical insurance system are underway, with a greater focus on innovative medicines and rare diseases as the number of shortlisted orphan drugs hits a record h... |
| 13.10.2024 | Sunvozertinib Granted Breakthrough Therapy Designation by China CDE for the First-Line Treatment of Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Fourth Breakthrough Therapy Designation for sunvozertinib in NSCLC with EGFR exon20ins
SHANGHAI, Oct. 13, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of canc... |
| 17.09.2024 | Subgroup Analysis from Pivotal WU-KONG1B Study Exhibits Robust Efficacy of Sunvozertinib in Non-Small Cell Lung Cancer Patients with EGFR Exon 20 Insertion Mutations Across Different Baseline Characte... | Results of subgroup analysis from the pivotal WU-KONG1B study in relapsed or refractory NSCLC with EGFR exon20ins presented at ESMO 2024
Sunvozertinib demonstrated promising anti-tumor efficacy, regardless of EGFR exon20ins region classific... |
| 19.06.2024 | Golidocitinib Approved in China as First-in-class JAK1 Only Inhibitor for the Treatment of Relapsed or Refractory Peripheral T-Cell Lymphoma | Golidocitinib is a first-in-class Janus kinase 1 (JAK1) only inhibitor approved for the treatment of r/r PTCL based on results from the multinational pivotal JACKPOT8B study.
Golidocitinib monotherapy demonstrated superior and durable clini... |
| 24.05.2024 | Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.
Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway.
T... |
| 24.05.2024 | Dizal Reveals New Findings from Biomarker Analysis, Highlighting Sunvozertinib as an Effective Treatment for Non-small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations | Anittumor efficacy of sunvozertinib was observed in patients regardless of baseline EGFR exon20ins status in plasma ctDNA.
Sunvozertinib could effectively clear EGFR exon20ins in plasma ctDNA, confirming its direct effect on EGFR pathway.
T... |
| 24.04.2024 | Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting | Topline results from Dizal's global pivotal phase II WU-KONG1 Part B study of sunvozertinib will be showcased in a featured oral presentation at the conference.
SHANGHAI, April 24, 2024 /PRNewswire/ -- Dizal (SSE:688192), a biopharmaceutica... |
| 07.04.2024 | FDA Grants Breakthrough Therapy Designation to Sunvozertinib for the First-Line Treatment of Patients with advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations | SHANGHAI, April 7, 2024 /PRNewswire/ -- Dizal (688192.SH) today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation (BTD) to its sunvozertinib as the first-line treatment for p... |
| 13.12.2023 | Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine | SHANGHAI, Dec. 13, 2023 /PRNewswire/ -- Dizal today announced that the results of a phase 2 pivotal study of sunvozertinib for the treatment of platinum-pretreated non-small-cell lung cancer (NSCLC) patients with EGFR exon 20 insertion muta... |
| 12.12.2023 | Dizal Impresses with Its Differentiated Hematological Oncology Portfolio at 2023 ASH | SHANGHAI, Dec. 12, 2023 /PRNewswire/ -- Dizal presented compelling data from its robust portfolio of hematological oncology at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition held in San Diego, California from De... |
| 10.12.2023 | Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH | Full analysis of multinational pivotal study results of golidocitinib in relapsed or refractory peripheral T-cell lymphoma (r/r PTCL) (JACKPOT8 PART B) simultaneously published in The Lancet Oncology and presented in oral session at the 65t... |
| 23.10.2023 | Sunvozertinib Demonstrates Best-in-Class Potential as a First-Line Treatment for EGFR Exon 20 Insertion Mutation-Positive Non-Small Cell Lung Cancer Patients | Sunvozertinib monotherapy demonstrated superior efficacy and excellent safety in patients in the 1st line setting for advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) Exon 20 insertion (... |
| 21.09.2023 | Golidocitinib Granted Priority Review by China NMPA for the Treatment of r/r PTCL | SHANGHAI, Sept. 21, 2023 /PRNewswire/ -- Dizal announced today that the China National Medical Products Administration (NMPA) has granted priority review status to golidocitinib, Dizal's investigational JAK1-only inhibitor, for the treatmen... |
| 14.09.2023 | Dizal Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL | SHANGHAI, Sept. 14, 2023 /PRNewswire/ -- Dizal today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for golidocitinib for the trea... |
| 10.09.2023 | Dizal Announces Clinical Results of Golidocitinib Published in Annals of Oncology | SHANGHAI, Sept. 10, 2023 /PRNewswire/ -- Dizal today announced the publication of the Phase I clinical data of golidocitinib for the treatment of relapsed or refractory (r/r) peripheral T cell lymphomas (PTCL) (JACKPOT8 PARTA) in Annals of ... |
| 23.08.2023 | Dizal's Sunvozertinib Approved by China NMPA with Potential for Best-in-class Therapy in NSCLC with EGFR Exon20ins Mutations | Sunvozertinib, a selective EGFR TKI targeting a wide spectrum of EGFR mutations, is the first Chinese Innovative drug approved for NSCLC Patients with EGFR Exon20ins
Approval based on the results of primary endpoint from WU-KONG6 study, whi... |
| 17.08.2023 | 2023WCLC Oral Presentation | Molecular Analysis Validates the Effectiveness of Tumor Tissue-Based and Plasma ctDNA Testing in Identifying NSCLC Patients with EGFR Exon20ins Eligible for Treatment with... | A high concordance was observed between tumor tissue-based and plasma circulating tumor DNA (ctDNA) testing in detecting EGFR exon 20 insertion (Exon20ins) mutations.
Both tumor tissue-based and plasma ctDNA testing can be used to identify ... |
| 07.06.2023 | Dizal Leads China's Biotech Innovation by Showcasing Strength of its Oncology Pipeline at 2023 ASCO | Two highly anticipated oral presentations captured attention: first pivotal study of sunvozertinib (WU-KONG6) and multinational pivotal study of golidocitinib (JACKPOT8)
Sunvozertinib achieved an ORR of 60.8% in ≥ second-line treatment and ... |
| 26.05.2023 | Dizal's Oncology Pipeline Continues to Impress with Two Oral Presentations at 2023 ASCO Annual Meeting | SHANGHAI, May 26, 2023 /PRNewswire/ -- Dizal (688192.SH) today announced that data from its oncology portfolio will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, June 2-6, 2023 in Chicago. The data wh... |
| 27.04.2023 | Dizal's Rapidly Evolving Oncology Pipeline to Make Waves at 2023 ASCO Meeting | Topline Results from Pivotal Studies of Sunvozertinib and Golidocitinib Selected for Oral Presentations
SHANGHAI, April 27, 2023 /PRNewswire/ -- Dizal today announced that multiple clinical data of its two leading assets – sunvozertinib and... |
| 10.01.2023 | Dizal Announces China CDE Acceptance of New Drug Application for Sunvozertinib for Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations | SHANGHAI, Jan. 10, 2023 /PRNewswire/ -- Dizal (SHEX: 688192) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) has accepted the New Drug Application (NDA) for sunvozertini... |
| 05.09.2022 | Dizal Announces Sunvozertinib Meets Primary Endpoint in its First Pivotal Study in Platinum-Pretreated NSCLC Patients with EGFR Exon20ins Mutations at 2022 ESMO | The confirmed objective response (cORR), as assessed by blinded independent central review (BICR), was 59.8% in advanced NSCLC with EGFR exon20ins mutations after at least one line of platinum-based chemotherapies
The response rate for pati... |
| 27.05.2022 | Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022 | Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures
Golidocitinib (DZD4205) demonstrates enormous potential for peripheral T-cell lym... |
| 13.05.2022 | Dizal Announces New Data from the Phase I/II Study of Golidocitnib in Refractory or Relapsed Peripheral T Cell Lymphoma Selected for Oral Presentation at 2022 EHA Annual Meeting | SHANGHAI, May 13, 2022 /PRNewswire/ -- Dizal (SSE: 688192) will present the data from an ongoing phase I/II study of golidocitnib, a selective JAK1 inhibitor, in refractory or relapsed peripheral T cell lymphoma (r/r PTCL) in oral session a... |
| 27.01.2022 | FDA Grants Breakthrough Therapy Designation for Dizal Pharmaceutical's DZD9008 in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring EGFR Exon20 Insertion | SHANGHAI, Jan. 27, 2022 /PRNewswire/ -- Dizal Pharmaceutical Co., Ltd. (SHEX:688192) ("Dizal"), today announced that the U.S. Food and Drug Administration ("FDA") has granted Breakthrough Therapy Designation to DZD9008 (... |
| 20.08.2020 | Chinese Dizal Pharma raises $100m from Lilly Asia, Sequoia, others | Premium
Dizal Pharmaceutical (Dizal Pharma) – a joint venture between state-owned SDIC Fund Management, Swedish drug maker AstraZeneca and Zytz Partners – has announced the completion of a $100-million round of financing led by Lilly Asia V... |
